Stock Market & Financial Investment News

News Breaks March 18, 2013 09:00 EDT INCY Incyte falls 13% Incyte is down 13%, or $3.24, to $21.60 News For INCY From The Last 14 Days Check below for free stories on INCY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 11:33 EDT INCY High option volume stocks: INCY AVT ABC GY EPB Subscribe for More Information 09:04 EDT INCY Wells Faro to host a conference 2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link 07:28 EDT INCY Wells Faro to host a conference Subscribe for More Information June 16, 2013 14:09 EDT INCY Jakafi improved overall survival in Phase III trial of patients with myelofibros Incyte (INCY) announced results from two ongoing clinical trials of Jakafi, ruxolitinib, an oral JAK1 and JAK2 inhibitor that is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, MF, that were presented at the 18th Congress of the European Hematology Associationm EHA, in Stockholm, Sweden. In a three-year follow-up analysis of the Phase III COMFORT-II study, treatment with Jakafi, which is marketed as Jakavi by Novartis (NVS) outside the United States, was associated with improved overall survival and sustained reductions in spleen size compared to best available therapy. In a separate exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial, by 48 months of treatment, Jakafi stabilized or reversed fibrosis of the bone marrow in 56 percent and 22 percent, respectively, of patients with MF, a magnitude of an effect not seen historically with best available therapy. June 13, 2013 07:48 EDT INCY Incyte Jakafi outlook still positive after label revisions, says Oppenheimer Subscribe for More Information 07:27 EDT INCY Incyte Jakafi label update expected, says UBS Subscribe for More Information 06:05 EDT INCY Eli Lilly, Incyte announce efficacy data of baricitinib Phase 2b JADA study Subscribe for More Information June 12, 2013 17:28 EDT INCY Incyte says prescribing information for Jakafi updated by U.S. FDA Subscribe for More Information 08:08 EDT INCY Incyte won't be hurt by patient illness, says Oppenheimer After a medical publication reported that a patient developed tumor lysis syndrome after discontinuing Incyte's Jakafi, Oppenheimer notes that the patient had previously been very sick. The firm views the data point as a significant outlier and keeps an Outperform rating on Incyte. June 11, 2013 13:18 EDT INCY Incyte Jakafi side effects raises some concerns, says Morgan Stanley Subscribe for More Information 13:11 EDT INCY Incyte mentioned cautiously at Morgan Stanley Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.